Cara Therapeutics names CMO
This article was originally published in Scrip
Executive Summary
Cara Therapeutics, a biopharmaceutical company focused on developing medicines for pain and pruritus by selectively targeting kappa opioid receptors, has named Joseph Stauffer chief medical officer. Dr Stauffer will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies. He has previously worked at a number of specialty pharma companies including Ikaria and Alpharma.